FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmacology, namely the use of a ligand-bound gold cluster for the treatment of depression, where said gold cluster includes a gold nucleus; and a ligand bound to a gold nucleus; where the gold nucleus has a diameter in range of 0.5-3 nm; ligand is one of selected from a group consisting of L-cysteine and its derivatives, D-cysteine and its derivatives, cysteine-containing oligopeptides and their derivatives and other thiol-containing compounds; L-cysteine and its derivatives are selected from the group consisting of L-cysteine, N-isobutyryl-L-cysteine (L-NIBC) and N-acetyl-L-cysteine (L-NAC); D-cysteine and its derivatives are selected from the group consisting of D-cysteine, N-isobutyryl-D-cysteine (D-NIBC) and N-acetyl-D-cysteine (D-NAC); cysteine-containing oligopeptides and derivatives thereof are cysteine-containing dipeptides, cysteine-containing tripeptides, cysteine-containing tetrapeptides or cysteine-containing pentapeptides; and other thiol-containing compounds are selected from the group consisting of 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L(D)-proline, thioglycolic acid, mercaptoethanol, thiophenol, D-3-trolovol, N-(2-mercaptopropionyl)-glycine, dodecylmercaptan, 2-aminoethanethiol (CSH), 3-mercaptopropionic acid (MPA) and 4-mercaptobenic acid (p-MBA).
EFFECT: disclosed is the use of a ligand-bound gold cluster for treating depression in a subject.
6 cl, 19 dwg, 1 tbl, 1 ex
